Top

Published in:

01-11-2019 | Ependymoma | Review Article

Central nervous system ependymoma: clinical implications of the new molecular classification, treatment guidelines and controversial issues

Authors: P. D. Delgado-López, E. M. Corrales-García, E. Alonso-García, R. García-Leal, R. González-Rodrigálvarez, E. Araus-Galdós, J. Martín-Alonso

Published in: Clinical and Translational Oncology | Issue 11/2019

Abstract

Ependymoma is an uncommon neuroepithelial tumor that may arise anywhere within the neuroaxis, both in children and in adults. It has been classically graded upon histopathological features, yet with limited clinical utility. Recently, DNA methylation profiling has provided a novel classification of ependymoma in nine molecular subgroups. This stratification method harbors prognostic value with supratentorial RELA-fusion and posterior fossa group A tumors showing a significantly shorter survival compared to the rest. Currently, the treatment of choice involves maximal safe resection and, in cases of residual disease, adjuvant conformal radiotherapy. Second-look surgery is also a feasible and recommended option for incompletely resected tumors. The role of chemotherapy is not yet established and can be considered in infants and children with relapsing disease or prior to re-intervention. Although targeted agents do not seem to play a role as adjuvant therapy, they are currently being tested for recurrent disease.

Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, Jensen P, et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell. 2005;8(4):323–35.CrossRefPubMed

Jung TY, Jung S, Kook H, Baek HJ. Treatment decisions of World Health Organization Grade II and III ependymomas in molecular era. J Korean Neurosurg Soc. 2018;61(3):312–8. https://doi.org/10.3340/jkns.2018.0003(Epub 2018 May 1).CrossRefPubMedPubMedCentral

Laviv Y, Germano IM, Mahadevan A, Kasper EM. Surgery for posterior fossa ependymomas in adults. J Neurosurg Sci. 2018;62(1):63–70. https://doi.org/10.23736/S0390-5616.17.04190-X(Epub 2017 Sep 22).CrossRefPubMed

Gerstner ER, Pajtler KW. Ependymoma. Semin Neurol. 2018;38(1):104–11. https://doi.org/10.1055/s-0038-1636503(Epub 2018 Mar 16).CrossRefPubMed

Purdy E, Johnston DL, Bartels U, Fryer C, Carret AS, Crooks B, et al. Ependymoma in children under the age of 3 years: a report from the Canadian pediatric brain tumour consortium. J Neurooncol. 2014;117(2):359–64. https://doi.org/10.1007/s11060-014-1396-3(Epub 2014 Feb 16).CrossRefPubMed

Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F, et al. Molecular classification of ependymal tumors across All CNS compartments, histopathological grades, and age groups. Cancer Cell. 2015;27(5):728–43. https://doi.org/10.1016/j.ccell.2015.04.002.CrossRefPubMedPubMedCentral

Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 2014;16(Suppl 4):iv1–63. https://doi.org/10.1093/neuonc/nou223.CrossRefPubMedPubMedCentral

Pajtler KW, Mack SC, Ramaswamy V, Smith CA, Witt H, Smith A, et al. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol. 2017;133(1):5–12. https://doi.org/10.1007/s00401-016-1643-0(Epub 2016 Nov 17).CrossRefPubMed

Sartor EA, Wen PY. Adjuvant treatments for ependymomas. J Neurosurg Sci. 2018;62(1):71–7. https://doi.org/10.23736/S0390-5616.17.04211-4(Epub 2017 Sep 22).CrossRefPubMed

10.

Khatua S, Ramaswamy V, Bouffet E. Current therapy and the evolving molecular landscape of paediatric ependymoma. Eur J Cancer. 2017;70:34–41. https://doi.org/10.1016/j.ejca.2016.10.013(Epub 2016 Nov 18).CrossRefPubMed

11.

Bouffet E, Tabori U, Huang A, Bartels U. Ependymoma: lessons from the past, prospects for the future. Childs Nerv Syst. 2009;25(11):1383–4. https://doi.org/10.1007/s00381-009-0915-6(Author reply 1385, Epub 2009 Jun 27).CrossRefPubMed

12.

Ellison DW, Kocak M, Figarella-Branger D, Felice G, Catherine G, Pietsch T, et al. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed. 2011;31(10):7. https://doi.org/10.1186/1477-5751-10-7.CrossRef

13.

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20. https://doi.org/10.1007/s00401-016-1545-1(Epub 2016 May 9).CrossRefPubMed

14.

Chavali P, Rao S, Palavalasa S, Bevinahalli N, Muthane YTC, Sadashiva N, et al. L1CAM immunopositivity in anaplastic supratentorial ependymomas: correlation with clinical and histological parameters. Int J Surg Pathol. 2018;1:1–9. https://doi.org/10.1177/1066896918800812(Epub ahead of print).CrossRef

15.

Parker M, Mohankumar KM, Punchihewa C, Weinlich R, Dalton JD, Li Y, et al. C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature. 2014;506(7489):451–5. https://doi.org/10.1038/nature13109(Epub 2014 Feb 19).CrossRefPubMedPubMedCentral

16.

Leeper H, Felicella MM, Walbert T. Recent advances in the classification and treatment of ependymomas. Curr Treat Options Oncol. 2017;18:55. https://doi.org/10.1007/s11864-017-0496-7.CrossRefPubMed

17.

Fassett DR, Pingree J, Kestle JR. The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients. Report of five cases and review of the literature. J Neurosurg. 2005;102((1 Suppl)):59–64.PubMed

18.

Godfraind C. Classification and controversies in pathology of ependymomas. Childs Nerv Syst. 2009;25(10):1185–93. https://doi.org/10.1007/s00381-008-0804-4(Epub 2009 Feb 11).CrossRefPubMed

19.

Khatami D, Kasper EM, Bhadelia R, Rojas R. Radiologic characteristics of ependymomas: a case-based approach. J Neurosurg Sci. 2018;62(1):38–45. https://doi.org/10.23736/S0390-5616.17.04151-0(Epub 2017 Sep 22).CrossRefPubMed

20.

Johnson DR, Guerin JB, Giannini C, Morris JM, Eckel LJ, Kaufmann TJ. Updates to the WHO brain tumor classification system: What the radiologist needs to know? Radiographics. 2016;37(7):2164–80. https://doi.org/10.1148/rg.2017170037(Epub 2017 Oct 13).CrossRef

21.

Vermuys K, Jeuris W, Vanhoenacker PK, Van Hoe L, D’Haenens P. Best cases from the AFIP: supratentorial ependymoma. Radiographics. 2005;25(2):486–90.CrossRef

22.

Merchant TE. Current clinical challenges in childhood ependymoma: a focused review. J Clin Oncol. 2017;35(21):2364–9. https://doi.org/10.1200/JCO.2017.73.1265(Epub 2017 Jun 22).CrossRefPubMed

23.

Horn B, Heideman R, Geyer R, Pollack I, Packer R, Goldwein J, et al. A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors. J Pediatr Hematol Oncol. 1999;21(3):203–11.CrossRefPubMed

24.

Cage TA, Clark AJ, Aranda D, Gupta N, Sun PP, Parsa AT, et al. A systematic review of treatment outcomes in pediatric patients with intracranial ependymomas. J Neurosurg Pediatr. 2013;11(6):673–81. https://doi.org/10.3171/2013.2.PEDS12345(Epub 2013 Mar 29).CrossRefPubMed

25.

Panwalkar P, Clark J, Ramaswamy V, Hawes D, Yang F, Dunham C, et al. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol. 2017;134(5):705–14. https://doi.org/10.1007/s00401-017-1752-4(Epub 2017 Jul 21).CrossRefPubMedPubMedCentral

26.

Healey EA, Barnes PD, Kupsky WJ, Scott RM, Sallan SE, Black PM, et al. The prognostic significance of postoperative residual tumor in ependymoma. Neurosurgery. 1991;28(5):666–71 (discussion 671–2).CrossRefPubMed

27.

Metellus P, Barrie M, Figarella-Branger D, Chinot O, Giorgi R, Gouvernet J, et al. Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. Brain. 2007;130(Pt 5):1338–49 (Epub 2007 Apr 19).CrossRefPubMed

28.

Paulino AC, Wen BC, Buatti JM, Hussey DH, Zhen WK, Mayr NA, et al. Intracranial ependymomas: an analysis of prognostic factors and patterns of failure. Am J Clin Oncol. 2002;25(2):117–22.CrossRefPubMed

29.

Sayegh ET, Aranda D, Kim JM, Oh T, Parsa AT, Oh MC. Prognosis by tumor location in adults with intracranial ependymomas. J Clin Neurosci. 2014;21(12):2096–101. https://doi.org/10.1016/j.jocn.2014.05.011(Epub 2014 Jul 15).CrossRefPubMedPubMedCentral

30.

Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, et al. Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro Oncol. 2015;17(3):440–7. https://doi.org/10.1093/neuonc/nou162(Epub 2014 Aug 13).CrossRefPubMed

31.

Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, et al. Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: a retrospective multicohort analysis. J Clin Oncol. 2016;34(21):2468–77. https://doi.org/10.1200/JCO.2015.65.7825(Epub 2016 Jun 6).CrossRefPubMedPubMedCentral

32.

Godfraind C, Kaczmarska JM, Kocak M, Dalton J, Wright KD, Sanford RA, et al. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. Acta Neuropathol. 2012;124(2):247–57. https://doi.org/10.1007/s00401-012-0981-9(Epub 2012 Apr 21).CrossRefPubMedPubMedCentral

33.

Swanson EL, Amdur RJ, Morris CG, Galloway TJ, Marcus RB Jr, Pincus DW, et al. Intracranial ependymomas treated with radiotherapy: long-term results from a single institution. J Neurooncol. 2011;102(3):451–7. https://doi.org/10.1007/s11060-010-0344-0(Epub 2010 Aug 13).CrossRefPubMed

34.

Merchant TE, Haida T, Wang MH, Finlay JL, Leibel SA. Anaplastic ependymoma: treatment of pediatric patients with or without craniospinal radiation therapy. J Neurosurg. 1997;86(6):943–9.CrossRefPubMed

35.

McLaughlin MP, Marcus RB Jr, Buatti JM, McCollough WM, Mickle JP, Kedar A, et al. Ependymoma: results, prognostic factors and treatment recommendations. Int J Radiat Oncol Biol Phys. 1998;40(4):845–50.CrossRefPubMed

36.

Schroeder TM, Chintagumpala M, Okcu MF, Chiu JK, Teh BS, Woo SY, et al. Intensity-modulated radiation therapy in childhood ependymoma. Int J Radiat Oncol Biol Phys. 2008;71(4):987–93. https://doi.org/10.1016/j.ijrobp.2007.11.058(Epub 2008 Feb 6).CrossRefPubMed

37.

Wu J, Armstrong TS, Gilbert MR. Biology and management of ependymomas. Neuro Oncol. 2016;18(7):902–13. https://doi.org/10.1093/neuonc/now016(Epub 2016 Mar 28).CrossRefPubMedPubMedCentral

38.

Merchant TE, Li C, Xiong X, Kun LE, Boop FA, Sanford RA. Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol. 2009;10(3):258–66.CrossRefPubMedPubMedCentral

39.

Macdonald SM, Sethi R, Lavally B, Yeap BY, Marcus KJ, Caruso P, et al. Proton radiotherapy for pediatric central nervous system ependymoma: clinical outcomes for 70 patients. Neuro Oncol. 2013;15(11):1552–9. https://doi.org/10.1093/neuonc/not121(Epub 2013 Oct 6).CrossRefPubMedPubMedCentral

40.

MacDonald SM, Safai S, Trofimov A, Wolfgang J, Fullerton B, Yeap BY, et al. Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. Int J Radiat Oncol Biol Phys. 2008;71(4):979–86. https://doi.org/10.1016/j.ijrobp.2007.11.065(Epub 2008 Mar 5).CrossRefPubMed

41.

Gunther JR, Sato M, Chintagumpala M, Ketonen L, Jones JY, Allen PK, et al. Imaging changes in pediatric intracranial ependymoma patients treated with proton beam radiation therapy compared to intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2015;93(1):54–63. https://doi.org/10.1016/j.ijrobp.2015.05.018(Epub 2015 May 16).CrossRefPubMed

42.

Kralik SF, Ho CY, Finke W, Buchsbaum JC, Haskins CP, Shih CS. Radiation necrosis in pediatric patients with brain tumors treated with proton radiotherapy. AJNR Am J Neuroradiol. 2015;36(8):1572–8. https://doi.org/10.3174/ajnr.A4333(Epub 2015 Jul 2).CrossRefPubMedPubMedCentral

43.

Grundy RG, Wilne SA, Weston CL, Robinson K, Lashford LS, Ironside J, et al. Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol. 2007;8(8):696–705.CrossRefPubMed

44.

Grill J, Le Deley MC, Gambarelli D, Raquin MA, Couanet D, Pierre-Kahn A, et al. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol. 2001;19(5):1288–96.CrossRefPubMed

45.

Venkatramani R, Ji L, Lasky J, Haley K, Judkins A, Zhou S, et al. Outcome of infants and young children with newly diagnosed ependymoma treated on the “Head Start” III prospective clinical trial. J Neurooncol. 2013;113(2):285–91. https://doi.org/10.1007/s11060-013-1111-9(Epub 2013 Mar 19).CrossRefPubMedPubMedCentral

46.

Garvin JH Jr., Selch MT, Holmes E, Berger MS, Finlay JL, Flannery A, et al. Phase II study of pre-irradiation chemotherapy for childhood intracranial ependymoma. Children’s Cancer Group protocol 9942: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2012;59(7):1183–9. https://doi.org/10.1002/pbc.24274(Epub 2012 Sep 4).CrossRefPubMed

47.

Foreman NK, Love S, Gill SS, Coakham HB. Second-look surgery for incompletely resected fourth ventricle ependymomas: technical case report. Neurosurgery. 1997;40(4):856–60 (discussion 860).CrossRefPubMed

48.

Eaton BR, Chowdhry V, Weaver K, Liu L, Ebb D, MacDonald SM, et al. Use of proton therapy for re-irradiation in pediatric intracranial ependymoma. Radiother Oncol. 2015;116(2):301–8. https://doi.org/10.1016/j.radonc.2015.07.023(Epub 2015 Aug 1).CrossRefPubMed

49.

Bouffet E, Hawkins CE, Ballourah W, Taylor MD, Bartels UK, Schoenhoff N, et al. Survival benefit for pediatric patients with recurrent ependymoma treated with reirradiation. Int J Radiat Oncol Biol Phys. 2012;83(5):1541–8. https://doi.org/10.1016/j.ijrobp.2011.10.039(Epub 2012 Jan 13).CrossRefPubMed

50.

Lobón MJ, Bautista F, Riet F, Dhermain F, Canale S, Dufour C, et al. Re-irradiation of recurrent pediatric ependymoma: modalities and outcomes: a twenty-year survey. Springerplus. 2016;5(1):879. https://doi.org/10.1186/s40064-016-2562-1.eCollection.CrossRefPubMedPubMedCentral

51.

Amirian ES, Armstrong TS, Aldape KD, Gilbert MR, Scheurer ME. Predictors of survival among pediatric and adult ependymoma cases: a study using surveillance, epidemiology, and end results data from 1973 to 2007. Neuroepidemiology. 2012;39(2):116–24. https://doi.org/10.1159/000339320(Epub 2012 Jul 28).CrossRefPubMed

52.

Vitanovics D, Bálint K, Hanzély Z, Banczerowski P, Afra D. Ependymoma in adults: surgery, reoperation and radiotherapy for survival. Pathol Oncol Res. 2010;16(1):93–9. https://doi.org/10.1007/s12253-009-9194-5(Epub 2009 Aug 30).CrossRefPubMed

53.

Guyotat J, Metellus P, Giorgi R, Barrie M, Jouvet A, Fevre-Montange M, et al. Infratentorial ependymomas: prognostic factors and outcome analysis in a multi-center retrospective series of 106 adult patients. Acta Neurochir (Wien). 2009;151(8):947–60. https://doi.org/10.1007/s00701-009-0417-z(Epub 2009 Jun 5).CrossRef

54.

Metellus P, Guyotat J, Chinot O, Durand A, Barrie M, Giorgi R, et al. Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients. Neuro Oncol. 2010;12(9):976–84. https://doi.org/10.1093/neuonc/noq047(Epub 2010 May 19).CrossRefPubMedPubMedCentral

55.

Gramatzki D, Roth P, Felsberg J, Hofer S, Rushing EJ, Hentschel B, et al. Chemotherapy for intracranial ependymoma in adults. BMC Cancer. 2016;23(16):287. https://doi.org/10.1186/s12885-016-2323-0.CrossRef

56.

Rudà R, Bosa C, Magistrello M, Franchino F, Pellerino A, Fiano V, et al. Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. Neuro Oncol. 2016;18(2):261–8. https://doi.org/10.1093/neuonc/nov167(Epub 2015 Aug 30).CrossRefPubMed

57.

DeWire M, Fouladi M, Turner DC, Wetmore C, Hawkins C, Jacobs C, et al. An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN). J Neurooncol. 2015;123(1):85–91. https://doi.org/10.1007/s11060-015-1764-7(Epub 2015 Apr 10).CrossRefPubMedPubMedCentral

58.

Gururangan S, Fangusaro J, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, et al. Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma—a pediatric brain tumor consortium study. Neuro Oncol. 2012;14(11):1404–12. https://doi.org/10.1093/neuonc/nos213(Epub 2012 Sep 26).CrossRefPubMedPubMedCentral

59.

Morris KA, Afridi SK, Evans DG, Hensiek AE, McCabe MG, Kellett M, et al. The response of spinal cord ependymomas to bevacizumab in patients with neurofibromatosis Type 2. J Neurosurg Spine. 2017;26(4):474–82. https://doi.org/10.3171/2016.8.spine16589(Epub 2016 Dec 16).CrossRef

60.

Kothbauer KF, Deletis V, Epstein FJ. Motor-evoked potential monitoring for intramedullary spinal cord tumor surgery: correlation of clinical and neurophysiological data in a series of 100 consecutive procedures. Neurosurg Focus. 1998;4(5):e1.CrossRefPubMed

61.

Deletis V, Seidel K, Sala F, Raabe A, Chudy D, Beck J. Intraoperative identification of the corticospinal tract and dorsal column of the spinal cord by electrical stimulation. J Neurol Neurosurg Psychiatry. 2018;89(7):754–61. https://doi.org/10.1136/jnnp-2017-317172(Epub 2018 Feb 7).CrossRefPubMed

62.

Deletis V, Bueno De Camargo A. Interventional neurophysiological mapping during spinal cord procedures. Stereotact Funct Neurosurg. 2001;77(1–4):25–8.CrossRefPubMed

63.

Nair D, Kumaraswamy VM, Braver D, Kilbride RD, Borges LF, Simon MV. Dorsal column mapping via phase reversal method: the refined technique and clinical applications. Neurosurgery. 2014;74:437–46.CrossRefPubMed

64.

MacDonald DB, Dong C, Quatrale R, Sala F, Skinner S, Soto F, et al. Recommendations of the International Society of Intraoperative neurophysiology for intraoperative somatosensory evoked potentials. Clin Neurophysiol. 2019;130(1):161–79. https://doi.org/10.1016/j.clinph.2018.10.008(Epub 2018 Nov 14).CrossRefPubMed

65.

Nuwer MR. New alert criteria for intraoperative somatosensory evoked potential monitoring. Clin Neurophysiol. 2019;130(1):155–6. https://doi.org/10.1016/j.clinph.2018.11.002(Epub 2018 Nov 10).CrossRefPubMed

66.

Deletis V, Sala F. Intraoperative neurophysiological monitoring of the spinal cord during spinal cord and spine surgery: a review focus on the corticospinal tracts. Clin Neurophysiol. 2008;119(2):248–64 (Epub 2007 Nov 28).CrossRefPubMed

67.

Sala F, Palandri G, Basso E, Lanteri P, Deletis V, Faccioli F, et al. Motor evoked potential monitoring improves outcome after surgery for intramedullary spinal cord tumors: a historical control study. Neurosurgery. 2006;58:1129–43.CrossRefPubMed

68.

Prokopienko M, Kunert P, Podgórska A, Marchel A. Surgical treatment of intramedullary ependymomas. Neurol Neurochir Pol. 2017;51(6):439–45. https://doi.org/10.1016/j.pjnns.2017.06.008(Epub 2017 Jul 8).CrossRefPubMed

69.

Sweeney KJ, Reynolds M, Farrell M, Bolger C. Gross total resection rates of grade II/III intramedullary ependymomas using the surgical strategy of en-bloc resection without intra-operative neurophysiological monitoring. Br J Neurosurg. 2017;31(3):364–8. https://doi.org/10.1080/02688697.2016.1270419(Epub 2016 Dec 25).CrossRefPubMed

70.

Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children’s Oncology Group phase I consortium report. J Clin Oncol. 2010;28(22):3623–9. https://doi.org/10.1200/JCO.2009.25.9119(Epub 2010 Jul 6).CrossRefPubMedPubMedCentral

71.

Jakacki RI, Foley MA, Horan J, Wang J, Kieran MW, Bowers DC, et al. Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study. J Neurooncol. 2016;129(1):131–8. https://doi.org/10.1007/s11060-016-2155-4(Epub 2016 Jun 10).CrossRefPubMed

72.

Wright KD, Daryani VM, Turner DC, Onar-Thomas A, Boulos N, et al. Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. Neuro Oncol. 2015;17(12):1620–7. https://doi.org/10.1093/neuonc/nov181(Epub 2015 Nov 4).CrossRefPubMedPubMedCentral

Title: Central nervous system ependymoma: clinical implications of the new molecular classification, treatment guidelines and controversial issues
Authors: P. D. Delgado-López
E. M. Corrales-García
E. Alonso-García
R. García-Leal
R. González-Rodrigálvarez
E. Araus-Galdós
J. Martín-Alonso
Publication date: 01-11-2019
Publisher: Springer International Publishing
Keywords: Ependymoma
Ependymoma
Radiotherapy
Ependymoma
Cytostatic Therapy
Published in: Clinical and Translational Oncology / Issue 11/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-019-02082-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2019

Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib

Expression of Concern: BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines

Neural stem cells promote glioblastoma formation in nude mice

Predictive factors for central lymph node and lateral cervical lymph node metastases in papillary thyroid carcinoma

Combined strategies for tumor immunotherapy with nanoparticles

Implication of lymph node staging in migration and different treatment strategies for stage T2N0M0 and T1N1M0 resected gastric cancer: a SEER population analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer